Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael C Sneller

Showing results (31-40 of 56) with videos related to

Pageof 6
Sort By:
Plos Pathogens|January 12, 2018
Effect of analytical treatment interruption and reinitiation of antiretroviral therapy on HIV reservoirs and immunologic parameters in infected individualsKatherine E Clarridge, Jana Blazkova, Kevin Einkauf, et al.
Plos One|August 28, 2019
Scalable, semi-automated fluorescence reduction neutralization assay for qualitative assessment of Ebola virus-neutralizing antibodies in human clinical samplesElena N Postnikova, James Pettitt, Collin J Van Ryn, et al.
Science Translational Medicine|September 7, 2019
An open-label phase 1 clinical trial of the anti-α<sub>4</sub>β<sub>7</sub> monoclonal antibody vedolizumab in HIV-infected individualsMichael C Sneller, Katherine E Clarridge, Catherine Seamon, et al.
Nature Medicine|October 29, 2021
Distinct mechanisms of long-term virologic control in two HIV-infected individuals after treatment interruption of anti-retroviral therapyJana Blazkova, Feng Gao, Manukumar Honnayakanahalli Marichannegowda, et al.
The Journal of Infectious Diseases|September 1, 2022
Identifying Paucisymptomatic or Asymptomatic and Unrecognized Ebola Virus Disease Among Close Contacts Based on Exposure Risk Assessments and Screening AlgorithmsDehkontee Gayedyu-Dennis, Mosoka P Fallah, Clara Drew, et al.
Blood|February 7, 2004
Severe chronic graft-versus-host disease is characterized by a preponderance of CD4(+) effector memory cells relative to central memory cellsKouhei Yamashita, Uimook Choi, Patricia C Woltz, et al.
The New England Journal of Medicine|March 12, 2019
A Longitudinal Study of Ebola Sequelae in Liberia, Michael C Sneller, Cavan Reilly, et al.
Nature Immunology|August 15, 2018
IgG3 regulates tissue-like memory B cells in HIV-infected individualsLela Kardava, Haewon Sohn, Christine Youn, et al.
JAMA Neurology|June 10, 2026
Neurological Manifestations in Adult Survivors of Ebola Virus DiseaseBridgette Jeanne Billioux, Cavan Reilly, Collin van Ryn, et al.
Nature|June 1, 2022
Combination anti-HIV antibodies provide sustained virological suppressionMichael C Sneller, Jana Blazkova, J Shawn Justement, et al.
Pageof 6

Showing results (31-40 of 56) with videos related to

Sort By:
Pageof 6
Plos Pathogens|January 12, 2018
Effect of analytical treatment interruption and reinitiation of antiretroviral therapy on HIV reservoirs and immunologic parameters in infected individualsKatherine E Clarridge, Jana Blazkova, Kevin Einkauf, et al.
Plos One|August 28, 2019
Scalable, semi-automated fluorescence reduction neutralization assay for qualitative assessment of Ebola virus-neutralizing antibodies in human clinical samplesElena N Postnikova, James Pettitt, Collin J Van Ryn, et al.
Science Translational Medicine|September 7, 2019
An open-label phase 1 clinical trial of the anti-α<sub>4</sub>β<sub>7</sub> monoclonal antibody vedolizumab in HIV-infected individualsMichael C Sneller, Katherine E Clarridge, Catherine Seamon, et al.
Nature Medicine|October 29, 2021
Distinct mechanisms of long-term virologic control in two HIV-infected individuals after treatment interruption of anti-retroviral therapyJana Blazkova, Feng Gao, Manukumar Honnayakanahalli Marichannegowda, et al.
The Journal of Infectious Diseases|September 1, 2022
Identifying Paucisymptomatic or Asymptomatic and Unrecognized Ebola Virus Disease Among Close Contacts Based on Exposure Risk Assessments and Screening AlgorithmsDehkontee Gayedyu-Dennis, Mosoka P Fallah, Clara Drew, et al.
Blood|February 7, 2004
Severe chronic graft-versus-host disease is characterized by a preponderance of CD4(+) effector memory cells relative to central memory cellsKouhei Yamashita, Uimook Choi, Patricia C Woltz, et al.
The New England Journal of Medicine|March 12, 2019
A Longitudinal Study of Ebola Sequelae in Liberia, Michael C Sneller, Cavan Reilly, et al.
Nature Immunology|August 15, 2018
IgG3 regulates tissue-like memory B cells in HIV-infected individualsLela Kardava, Haewon Sohn, Christine Youn, et al.
JAMA Neurology|June 10, 2026
Neurological Manifestations in Adult Survivors of Ebola Virus DiseaseBridgette Jeanne Billioux, Cavan Reilly, Collin van Ryn, et al.
Nature|June 1, 2022
Combination anti-HIV antibodies provide sustained virological suppressionMichael C Sneller, Jana Blazkova, J Shawn Justement, et al.
Pageof 6